nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—Polydipsia—Furosemide—dilated cardiomyopathy	0.0244	0.0312	CcSEcCtD
Aprepitant—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.0244	0.0312	CcSEcCtD
Aprepitant—Epigastric discomfort—Furosemide—dilated cardiomyopathy	0.0144	0.0184	CcSEcCtD
Aprepitant—Lethargy—Spironolactone—dilated cardiomyopathy	0.0103	0.0132	CcSEcCtD
Aprepitant—TACR3—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.01	0.0459	CbGpPWpGaD
Aprepitant—Inappropriate antidiuretic hormone secretion—Lisinopril—dilated cardiomyopathy	0.00976	0.0125	CcSEcCtD
Aprepitant—Glycosuria—Furosemide—dilated cardiomyopathy	0.00933	0.0119	CcSEcCtD
Aprepitant—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00932	0.0119	CcSEcCtD
Aprepitant—TACR3—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00932	0.0426	CbGpPWpGaD
Aprepitant—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00922	0.0118	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00908	0.0116	CcSEcCtD
Aprepitant—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00908	0.0116	CcSEcCtD
Aprepitant—Gastritis—Spironolactone—dilated cardiomyopathy	0.00893	0.0114	CcSEcCtD
Aprepitant—Heartburn—Lisinopril—dilated cardiomyopathy	0.00824	0.0105	CcSEcCtD
Aprepitant—TACR3—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00771	0.0353	CbGpPWpGaD
Aprepitant—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00771	0.00986	CcSEcCtD
Aprepitant—Renal failure—Spironolactone—dilated cardiomyopathy	0.00764	0.00978	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00721	0.033	CbGpPWpGaD
Aprepitant—Urine output increased—Furosemide—dilated cardiomyopathy	0.00684	0.00875	CcSEcCtD
Aprepitant—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.0066	0.00845	CcSEcCtD
Aprepitant—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00646	0.00826	CcSEcCtD
Aprepitant—Chest discomfort—Lisinopril—dilated cardiomyopathy	0.00641	0.00821	CcSEcCtD
Aprepitant—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00637	0.00815	CcSEcCtD
Aprepitant—Thrombophlebitis—Furosemide—dilated cardiomyopathy	0.00634	0.00811	CcSEcCtD
Aprepitant—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00631	0.00808	CcSEcCtD
Aprepitant—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00625	0.008	CcSEcCtD
Aprepitant—Polyuria—Furosemide—dilated cardiomyopathy	0.00625	0.008	CcSEcCtD
Aprepitant—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.00624	0.00798	CcSEcCtD
Aprepitant—Alopecia—Spironolactone—dilated cardiomyopathy	0.00617	0.00789	CcSEcCtD
Aprepitant—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00584	0.00748	CcSEcCtD
Aprepitant—Thirst—Furosemide—dilated cardiomyopathy	0.00577	0.00738	CcSEcCtD
Aprepitant—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00574	0.00735	CcSEcCtD
Aprepitant—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00567	0.00726	CcSEcCtD
Aprepitant—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00564	0.00721	CcSEcCtD
Aprepitant—Lethargy—Furosemide—dilated cardiomyopathy	0.0056	0.00717	CcSEcCtD
Aprepitant—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00551	0.00705	CcSEcCtD
Aprepitant—Wheezing—Lisinopril—dilated cardiomyopathy	0.00551	0.00705	CcSEcCtD
Aprepitant—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00551	0.00705	CcSEcCtD
Aprepitant—Malaise—Spironolactone—dilated cardiomyopathy	0.00548	0.00701	CcSEcCtD
Aprepitant—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00536	0.00685	CcSEcCtD
Aprepitant—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00514	0.00658	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00513	0.0235	CbGpPWpGaD
Aprepitant—Discomfort—Spironolactone—dilated cardiomyopathy	0.00511	0.00654	CcSEcCtD
Aprepitant—Dehydration—Furosemide—dilated cardiomyopathy	0.0051	0.00653	CcSEcCtD
Aprepitant—Confusional state—Spironolactone—dilated cardiomyopathy	0.005	0.0064	CcSEcCtD
Aprepitant—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00499	0.00639	CcSEcCtD
Aprepitant—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00496	0.00635	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00494	0.00633	CcSEcCtD
Aprepitant—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00494	0.00633	CcSEcCtD
Aprepitant—TACR1—Peptide GPCRs—AGTR2—dilated cardiomyopathy	0.0049	0.0224	CbGpPWpGaD
Aprepitant—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00485	0.00621	CcSEcCtD
Aprepitant—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00484	0.0062	CcSEcCtD
Aprepitant—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00478	0.00611	CcSEcCtD
Aprepitant—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00473	0.00606	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.00472	0.0216	CbGpPWpGaD
Aprepitant—TACR3—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.00472	0.0216	CbGpPWpGaD
Aprepitant—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00469	0.006	CcSEcCtD
Aprepitant—TACR1—Peptide GPCRs—CXCR3—dilated cardiomyopathy	0.00455	0.0208	CbGpPWpGaD
Aprepitant—Somnolence—Spironolactone—dilated cardiomyopathy	0.00441	0.00564	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00438	0.0201	CbGpPWpGaD
Aprepitant—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00438	0.00561	CcSEcCtD
Aprepitant—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00433	0.00554	CcSEcCtD
Aprepitant—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00433	0.00554	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00428	0.00548	CcSEcCtD
Aprepitant—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00428	0.00548	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00419	0.00537	CcSEcCtD
Aprepitant—Renal failure—Furosemide—dilated cardiomyopathy	0.00416	0.00532	CcSEcCtD
Aprepitant—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00413	0.00529	CcSEcCtD
Aprepitant—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00412	0.00527	CcSEcCtD
Aprepitant—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00409	0.00523	CcSEcCtD
Aprepitant—Urticaria—Spironolactone—dilated cardiomyopathy	0.00394	0.00504	CcSEcCtD
Aprepitant—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00392	0.00502	CcSEcCtD
Aprepitant—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00386	0.00494	CcSEcCtD
Aprepitant—Dehydration—Lisinopril—dilated cardiomyopathy	0.00383	0.0049	CcSEcCtD
Aprepitant—TACR1—Peptide GPCRs—AGTR1—dilated cardiomyopathy	0.00377	0.0172	CbGpPWpGaD
Aprepitant—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00375	0.0048	CcSEcCtD
Aprepitant—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00372	0.00476	CcSEcCtD
Aprepitant—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00372	0.00476	CcSEcCtD
Aprepitant—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00371	0.00475	CcSEcCtD
Aprepitant—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00371	0.00475	CcSEcCtD
Aprepitant—TACR3—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00367	0.0168	CbGpPWpGaD
Aprepitant—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00365	0.00468	CcSEcCtD
Aprepitant—Gastritis—Lisinopril—dilated cardiomyopathy	0.00364	0.00466	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00363	0.0166	CbGpPWpGaD
Aprepitant—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00359	0.00459	CcSEcCtD
Aprepitant—Eye disorder—Furosemide—dilated cardiomyopathy	0.00355	0.00454	CcSEcCtD
Aprepitant—Tinnitus—Furosemide—dilated cardiomyopathy	0.00354	0.00453	CcSEcCtD
Aprepitant—Pruritus—Spironolactone—dilated cardiomyopathy	0.00351	0.00449	CcSEcCtD
Aprepitant—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00347	0.00444	CcSEcCtD
Aprepitant—Angiopathy—Furosemide—dilated cardiomyopathy	0.00344	0.00441	CcSEcCtD
Aprepitant—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00343	0.00439	CcSEcCtD
Aprepitant—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00339	0.00434	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00337	0.0154	CbGpPWpGaD
Aprepitant—Dysuria—Lisinopril—dilated cardiomyopathy	0.00333	0.00426	CcSEcCtD
Aprepitant—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00333	0.00426	CcSEcCtD
Aprepitant—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00331	0.00423	CcSEcCtD
Aprepitant—Malnutrition—Furosemide—dilated cardiomyopathy	0.00331	0.00423	CcSEcCtD
Aprepitant—Erythema—Furosemide—dilated cardiomyopathy	0.00331	0.00423	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.00329	0.015	CbGpPWpGaD
Aprepitant—Dizziness—Spironolactone—dilated cardiomyopathy	0.00328	0.0042	CcSEcCtD
Aprepitant—Flatulence—Furosemide—dilated cardiomyopathy	0.00326	0.00417	CcSEcCtD
Aprepitant—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00325	0.00416	CcSEcCtD
Aprepitant—Weight increased—Lisinopril—dilated cardiomyopathy	0.00324	0.00415	CcSEcCtD
Aprepitant—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00324	0.00414	CcSEcCtD
Aprepitant—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00322	0.00412	CcSEcCtD
Aprepitant—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00321	0.00411	CcSEcCtD
Aprepitant—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00319	0.00409	CcSEcCtD
Aprepitant—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00318	0.00407	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00316	0.0145	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00316	0.0145	CbGpPWpGaD
Aprepitant—Vomiting—Spironolactone—dilated cardiomyopathy	0.00315	0.00403	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00315	0.00403	CcSEcCtD
Aprepitant—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00313	0.004	CcSEcCtD
Aprepitant—Rash—Spironolactone—dilated cardiomyopathy	0.00313	0.004	CcSEcCtD
Aprepitant—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00312	0.004	CcSEcCtD
Aprepitant—Renal failure—Lisinopril—dilated cardiomyopathy	0.00312	0.00399	CcSEcCtD
Aprepitant—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00311	0.00398	CcSEcCtD
Aprepitant—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00311	0.00398	CcSEcCtD
Aprepitant—Headache—Spironolactone—dilated cardiomyopathy	0.00311	0.00398	CcSEcCtD
Aprepitant—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00308	0.00395	CcSEcCtD
Aprepitant—Anaemia—Furosemide—dilated cardiomyopathy	0.00305	0.00391	CcSEcCtD
Aprepitant—Haematuria—Lisinopril—dilated cardiomyopathy	0.00303	0.00387	CcSEcCtD
Aprepitant—Nausea—Spironolactone—dilated cardiomyopathy	0.00295	0.00377	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00294	0.0135	CbGpPWpGaD
Aprepitant—Bradycardia—Lisinopril—dilated cardiomyopathy	0.0029	0.00371	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00285	0.013	CbGpPWpGaD
Aprepitant—Hallucination—Lisinopril—dilated cardiomyopathy	0.00283	0.00363	CcSEcCtD
Aprepitant—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00283	0.00362	CcSEcCtD
Aprepitant—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00281	0.0036	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00279	0.00358	CcSEcCtD
Aprepitant—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00279	0.00357	CcSEcCtD
Aprepitant—Dry mouth—Furosemide—dilated cardiomyopathy	0.00275	0.00352	CcSEcCtD
Aprepitant—Confusional state—Furosemide—dilated cardiomyopathy	0.00272	0.00348	CcSEcCtD
Aprepitant—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.0027	0.00345	CcSEcCtD
Aprepitant—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00269	0.00345	CcSEcCtD
Aprepitant—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00266	0.0034	CcSEcCtD
Aprepitant—Shock—Furosemide—dilated cardiomyopathy	0.00265	0.0034	CcSEcCtD
Aprepitant—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00265	0.00339	CcSEcCtD
Aprepitant—Flushing—Lisinopril—dilated cardiomyopathy	0.00264	0.00338	CcSEcCtD
Aprepitant—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00264	0.00338	CcSEcCtD
Aprepitant—Skin disorder—Furosemide—dilated cardiomyopathy	0.00262	0.00335	CcSEcCtD
Aprepitant—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00261	0.00334	CcSEcCtD
Aprepitant—TACR3—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00258	0.0118	CbGpPWpGaD
Aprepitant—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00258	0.00331	CcSEcCtD
Aprepitant—Anorexia—Furosemide—dilated cardiomyopathy	0.00257	0.00329	CcSEcCtD
Aprepitant—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00257	0.00329	CcSEcCtD
Aprepitant—Chills—Lisinopril—dilated cardiomyopathy	0.00256	0.00327	CcSEcCtD
Aprepitant—TACR3—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00255	0.0117	CbGpPWpGaD
Aprepitant—Hypotension—Furosemide—dilated cardiomyopathy	0.00252	0.00323	CcSEcCtD
Aprepitant—Alopecia—Lisinopril—dilated cardiomyopathy	0.00252	0.00322	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.00251	0.0115	CbGpPWpGaD
Aprepitant—Mental disorder—Lisinopril—dilated cardiomyopathy	0.0025	0.00319	CcSEcCtD
Aprepitant—Erythema—Lisinopril—dilated cardiomyopathy	0.00248	0.00317	CcSEcCtD
Aprepitant—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00248	0.00317	CcSEcCtD
Aprepitant—Flatulence—Lisinopril—dilated cardiomyopathy	0.00244	0.00313	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00243	0.0111	CbGpPWpGaD
Aprepitant—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00243	0.00311	CcSEcCtD
Aprepitant—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00242	0.0031	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00241	0.011	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00241	0.011	CbGpPWpGaD
Aprepitant—Back pain—Lisinopril—dilated cardiomyopathy	0.0024	0.00307	CcSEcCtD
Aprepitant—Somnolence—Furosemide—dilated cardiomyopathy	0.0024	0.00307	CcSEcCtD
Aprepitant—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00238	0.00305	CcSEcCtD
Aprepitant—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00234	0.003	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00233	0.00298	CcSEcCtD
Aprepitant—Fatigue—Furosemide—dilated cardiomyopathy	0.00233	0.00298	CcSEcCtD
Aprepitant—Tremor—Lisinopril—dilated cardiomyopathy	0.00232	0.00297	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00231	0.0106	CbGpPWpGaD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00231	0.0106	CbGpPWpGaD
Aprepitant—Constipation—Furosemide—dilated cardiomyopathy	0.00231	0.00295	CcSEcCtD
Aprepitant—Pain—Furosemide—dilated cardiomyopathy	0.00231	0.00295	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—AGTR2—dilated cardiomyopathy	0.0023	0.0105	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—CXCL2—dilated cardiomyopathy	0.0023	0.0105	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.0023	0.00294	CcSEcCtD
Aprepitant—Anaemia—Lisinopril—dilated cardiomyopathy	0.00229	0.00293	CcSEcCtD
Aprepitant—Angioedema—Lisinopril—dilated cardiomyopathy	0.00227	0.0029	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00224	0.0102	CbGpPWpGaD
Aprepitant—Malaise—Lisinopril—dilated cardiomyopathy	0.00224	0.00286	CcSEcCtD
Aprepitant—Syncope—Lisinopril—dilated cardiomyopathy	0.00222	0.00285	CcSEcCtD
Aprepitant—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00222	0.00284	CcSEcCtD
Aprepitant—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00221	0.00282	CcSEcCtD
Aprepitant—Palpitations—Lisinopril—dilated cardiomyopathy	0.00219	0.0028	CcSEcCtD
Aprepitant—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00218	0.00279	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00217	0.00992	CbGpPWpGaD
Aprepitant—Cough—Lisinopril—dilated cardiomyopathy	0.00216	0.00277	CcSEcCtD
Aprepitant—Urticaria—Furosemide—dilated cardiomyopathy	0.00214	0.00274	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—CXCR3—dilated cardiomyopathy	0.00214	0.00979	CbGpPWpGaD
Aprepitant—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00213	0.00273	CcSEcCtD
Aprepitant—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00213	0.00273	CcSEcCtD
Aprepitant—Myalgia—Lisinopril—dilated cardiomyopathy	0.00211	0.0027	CcSEcCtD
Aprepitant—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00211	0.0027	CcSEcCtD
Aprepitant—Chest pain—Lisinopril—dilated cardiomyopathy	0.00211	0.0027	CcSEcCtD
Aprepitant—Anxiety—Lisinopril—dilated cardiomyopathy	0.0021	0.00269	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.0021	0.00268	CcSEcCtD
Aprepitant—Discomfort—Lisinopril—dilated cardiomyopathy	0.00209	0.00267	CcSEcCtD
Aprepitant—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00206	0.00264	CcSEcCtD
Aprepitant—Confusional state—Lisinopril—dilated cardiomyopathy	0.00204	0.00261	CcSEcCtD
Aprepitant—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00202	0.00259	CcSEcCtD
Aprepitant—Oedema—Lisinopril—dilated cardiomyopathy	0.00202	0.00259	CcSEcCtD
Aprepitant—Infection—Lisinopril—dilated cardiomyopathy	0.00201	0.00257	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.002	0.00917	CbGpPWpGaD
Aprepitant—Shock—Lisinopril—dilated cardiomyopathy	0.00199	0.00255	CcSEcCtD
Aprepitant—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00199	0.00254	CcSEcCtD
Aprepitant—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00198	0.00254	CcSEcCtD
Aprepitant—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00198	0.00253	CcSEcCtD
Aprepitant—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00197	0.00252	CcSEcCtD
Aprepitant—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00196	0.0025	CcSEcCtD
Aprepitant—Asthenia—Furosemide—dilated cardiomyopathy	0.00194	0.00248	CcSEcCtD
Aprepitant—Anorexia—Lisinopril—dilated cardiomyopathy	0.00193	0.00247	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.00191	0.00873	CbGpPWpGaD
Aprepitant—Pruritus—Furosemide—dilated cardiomyopathy	0.00191	0.00244	CcSEcCtD
Aprepitant—Hypotension—Lisinopril—dilated cardiomyopathy	0.00189	0.00242	CcSEcCtD
Aprepitant—CYP2C19—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00187	0.00856	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00185	0.00847	CbGpPWpGaD
Aprepitant—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00185	0.00236	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00184	0.00236	CcSEcCtD
Aprepitant—Insomnia—Lisinopril—dilated cardiomyopathy	0.00183	0.00234	CcSEcCtD
Aprepitant—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00182	0.00233	CcSEcCtD
Aprepitant—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.0018	0.00231	CcSEcCtD
Aprepitant—Somnolence—Lisinopril—dilated cardiomyopathy	0.0018	0.0023	CcSEcCtD
Aprepitant—TACR1—G alpha (q) signalling events—AGTR1—dilated cardiomyopathy	0.00179	0.0082	CbGpPWpGaD
Aprepitant—Dizziness—Furosemide—dilated cardiomyopathy	0.00178	0.00228	CcSEcCtD
Aprepitant—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00178	0.00228	CcSEcCtD
Aprepitant—TACR1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.00177	0.0081	CbGpPWpGaD
Aprepitant—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00176	0.00225	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.00176	0.00804	CbGpPWpGaD
Aprepitant—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00175	0.00224	CcSEcCtD
Aprepitant—Fatigue—Lisinopril—dilated cardiomyopathy	0.00174	0.00223	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00174	0.00795	CbGpPWpGaD
Aprepitant—Pain—Lisinopril—dilated cardiomyopathy	0.00173	0.00222	CcSEcCtD
Aprepitant—Constipation—Lisinopril—dilated cardiomyopathy	0.00173	0.00222	CcSEcCtD
Aprepitant—Vomiting—Furosemide—dilated cardiomyopathy	0.00172	0.0022	CcSEcCtD
Aprepitant—TACR3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00171	0.00783	CbGpPWpGaD
Aprepitant—Rash—Furosemide—dilated cardiomyopathy	0.0017	0.00218	CcSEcCtD
Aprepitant—Dermatitis—Furosemide—dilated cardiomyopathy	0.0017	0.00217	CcSEcCtD
Aprepitant—Headache—Furosemide—dilated cardiomyopathy	0.00169	0.00216	CcSEcCtD
Aprepitant—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00167	0.00213	CcSEcCtD
Aprepitant—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00166	0.00212	CcSEcCtD
Aprepitant—Urticaria—Lisinopril—dilated cardiomyopathy	0.00161	0.00206	CcSEcCtD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.0016	0.00734	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—dilated cardiomyopathy	0.0016	0.00734	CbGpPWpGaD
Aprepitant—Nausea—Furosemide—dilated cardiomyopathy	0.0016	0.00205	CcSEcCtD
Aprepitant—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.0016	0.00205	CcSEcCtD
Aprepitant—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.0016	0.00205	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00155	0.00707	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00155	0.00707	CbGpPWpGaD
Aprepitant—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00149	0.00191	CcSEcCtD
Aprepitant—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00146	0.00667	CbGpPWpGaD
Aprepitant—Asthenia—Lisinopril—dilated cardiomyopathy	0.00145	0.00186	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00144	0.00657	CbGpPWpGaD
Aprepitant—Pruritus—Lisinopril—dilated cardiomyopathy	0.00143	0.00183	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00139	0.00636	CbGpPWpGaD
Aprepitant—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00138	0.00177	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00136	0.00623	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00136	0.00623	CbGpPWpGaD
Aprepitant—Dizziness—Lisinopril—dilated cardiomyopathy	0.00134	0.00171	CcSEcCtD
Aprepitant—TACR3—GPCR ligand binding—AGT—dilated cardiomyopathy	0.0013	0.00596	CbGpPWpGaD
Aprepitant—Vomiting—Lisinopril—dilated cardiomyopathy	0.00129	0.00165	CcSEcCtD
Aprepitant—Rash—Lisinopril—dilated cardiomyopathy	0.00128	0.00163	CcSEcCtD
Aprepitant—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00127	0.00163	CcSEcCtD
Aprepitant—Headache—Lisinopril—dilated cardiomyopathy	0.00127	0.00162	CcSEcCtD
Aprepitant—TACR3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00127	0.00579	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.00126	0.00577	CbGpPWpGaD
Aprepitant—TACR1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.00125	0.0057	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.00124	0.00565	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.00124	0.00565	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.00123	0.00561	CbGpPWpGaD
Aprepitant—Nausea—Lisinopril—dilated cardiomyopathy	0.0012	0.00154	CcSEcCtD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00119	0.00543	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00118	0.00538	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00118	0.00538	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.00115	0.00526	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.00113	0.00516	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00113	0.00515	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00111	0.00509	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.0011	0.00503	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00109	0.005	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00106	0.00484	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00105	0.00479	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000993	0.00454	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000951	0.00435	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000905	0.00414	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000902	0.00412	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—EGFR—dilated cardiomyopathy	0.000868	0.00397	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000858	0.00393	CbGpPWpGaD
Aprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000836	0.00382	CbGpPWpGaD
Aprepitant—CYP2C19—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00083	0.00379	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—TNF—dilated cardiomyopathy	0.000827	0.00378	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000823	0.00376	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000784	0.00358	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000771	0.00353	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000757	0.00346	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000737	0.00337	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00073	0.00334	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00073	0.00334	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.0007	0.0032	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000679	0.00311	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000673	0.00308	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000669	0.00306	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000665	0.00304	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000665	0.00304	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000661	0.00302	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000658	0.00301	CbGpPWpGaD
Aprepitant—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000647	0.00296	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000637	0.00291	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000618	0.00283	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000604	0.00276	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000604	0.00276	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000599	0.00274	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000562	0.00257	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000561	0.00257	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000544	0.00249	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	0.000537	0.00246	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000533	0.00244	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000513	0.00235	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000511	0.00234	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000485	0.00222	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000483	0.00221	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000468	0.00214	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000464	0.00212	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000464	0.00212	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000458	0.00209	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00044	0.00201	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.00044	0.00201	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000421	0.00192	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000414	0.00189	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000409	0.00187	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000402	0.00184	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.0004	0.00183	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—AGT—dilated cardiomyopathy	0.000395	0.00181	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	0.000385	0.00176	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000377	0.00172	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000376	0.00172	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00036	0.00165	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000357	0.00163	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000357	0.00163	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	0.000348	0.00159	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000342	0.00156	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000332	0.00152	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000327	0.00149	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000321	0.00147	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000318	0.00146	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000296	0.00135	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000288	0.00132	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000288	0.00132	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000278	0.00127	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000275	0.00126	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000275	0.00126	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000274	0.00125	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000274	0.00125	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.00026	0.00119	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	0.000251	0.00115	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ANKRD1—dilated cardiomyopathy	0.000229	0.00105	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000227	0.00104	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000224	0.00102	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—TAZ—dilated cardiomyopathy	0.000215	0.000983	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000208	0.000953	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000202	0.000924	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000196	0.000896	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—SDHA—dilated cardiomyopathy	0.000194	0.000889	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—AGT—dilated cardiomyopathy	0.000193	0.000883	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000188	0.00086	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000178	0.000815	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.000177	0.000811	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000167	0.000766	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000155	0.000711	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.000151	0.000693	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000137	0.000629	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000134	0.000613	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000129	0.000591	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000119	0.000542	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000117	0.000535	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000115	0.000528	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000108	0.000494	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000105	0.000482	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000104	0.000476	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	9.48e-05	0.000434	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	9.45e-05	0.000432	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.24e-05	0.000423	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	9.2e-05	0.000421	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—dilated cardiomyopathy	9.19e-05	0.00042	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	9e-05	0.000412	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	8.29e-05	0.000379	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.1e-05	0.000371	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	6.83e-05	0.000312	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	6.65e-05	0.000304	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	5.99e-05	0.000274	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GPX1—dilated cardiomyopathy	5.28e-05	0.000242	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CD36—dilated cardiomyopathy	5.14e-05	0.000235	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.82e-05	0.00022	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	4.69e-05	0.000214	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—AGT—dilated cardiomyopathy	4.63e-05	0.000212	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	4.22e-05	0.000193	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	4.11e-05	0.000188	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	4.01e-05	0.000183	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.61e-05	0.000165	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	3.18e-05	0.000145	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	3.09e-05	0.000141	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.78e-05	0.000127	CbGpPWpGaD
